GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001603222 | Liver | HCC | viral process | 286/7958 | 415/18723 | 4.41e-28 | 1.86e-25 | 286 |
GO:003497612 | Liver | HCC | response to endoplasmic reticulum stress | 189/7958 | 256/18723 | 1.43e-24 | 4.06e-22 | 189 |
GO:003596612 | Liver | HCC | response to topologically incorrect protein | 123/7958 | 159/18723 | 2.60e-19 | 3.44e-17 | 123 |
GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
GO:001908021 | Liver | HCC | viral gene expression | 77/7958 | 94/18723 | 4.33e-15 | 3.12e-13 | 77 |
GO:000698612 | Liver | HCC | response to unfolded protein | 103/7958 | 137/18723 | 6.50e-15 | 4.48e-13 | 103 |
GO:003596712 | Liver | HCC | cellular response to topologically incorrect protein | 89/7958 | 116/18723 | 5.61e-14 | 3.39e-12 | 89 |
GO:003462012 | Liver | HCC | cellular response to unfolded protein | 71/7958 | 96/18723 | 3.70e-10 | 1.22e-08 | 71 |
GO:003096811 | Liver | HCC | endoplasmic reticulum unfolded protein response | 56/7958 | 74/18723 | 6.47e-09 | 1.67e-07 | 56 |
GO:000916512 | Liver | HCC | nucleotide biosynthetic process | 150/7958 | 254/18723 | 6.79e-08 | 1.40e-06 | 150 |
GO:190129312 | Liver | HCC | nucleoside phosphate biosynthetic process | 151/7958 | 256/18723 | 6.84e-08 | 1.41e-06 | 151 |
GO:001908211 | Liver | HCC | viral protein processing | 23/7958 | 29/18723 | 5.86e-05 | 5.38e-04 | 23 |
GO:007190021 | Liver | HCC | regulation of protein serine/threonine kinase activity | 189/7958 | 359/18723 | 5.97e-05 | 5.47e-04 | 189 |
GO:004586021 | Liver | HCC | positive regulation of protein kinase activity | 194/7958 | 386/18723 | 1.16e-03 | 6.54e-03 | 194 |
GO:003367411 | Liver | HCC | positive regulation of kinase activity | 230/7958 | 467/18723 | 1.72e-03 | 8.95e-03 | 230 |
GO:0072525 | Liver | HCC | pyridine-containing compound biosynthetic process | 22/7958 | 32/18723 | 2.43e-03 | 1.18e-02 | 22 |
GO:0072524 | Liver | HCC | pyridine-containing compound metabolic process | 25/7958 | 38/18723 | 3.18e-03 | 1.47e-02 | 25 |
GO:0070213 | Liver | HCC | protein auto-ADP-ribosylation | 10/7958 | 12/18723 | 4.79e-03 | 2.02e-02 | 10 |
GO:003649811 | Liver | HCC | IRE1-mediated unfolded protein response | 14/7958 | 19/18723 | 5.94e-03 | 2.44e-02 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARP16 | SNV | Missense_Mutation | | c.418G>A | p.Glu140Lys | p.E140K | Q8N5Y8 | protein_coding | tolerated(0.21) | benign(0.043) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PARP16 | SNV | Missense_Mutation | rs762932743 | c.776N>G | p.Asn259Ser | p.N259S | Q8N5Y8 | protein_coding | tolerated(0.05) | possibly_damaging(0.768) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
PARP16 | insertion | In_Frame_Ins | novel | c.198_199insGTTTGTGAGAGACTCATTTCTTTTCCAAGTAATGACTCAGATTAC | p.Pro66_Asn67insValCysGluArgLeuIleSerPheProSerAsnAspSerAspTyr | p.P66_N67insVCERLISFPSNDSDY | Q8N5Y8 | protein_coding | | | TCGA-A8-A09K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP16 | SNV | Missense_Mutation | | c.434G>T | p.Arg145Leu | p.R145L | Q8N5Y8 | protein_coding | tolerated(0.07) | benign(0.34) | TCGA-Q1-A73R-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PARP16 | SNV | Missense_Mutation | | c.413N>G | p.Phe138Cys | p.F138C | Q8N5Y8 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
PARP16 | SNV | Missense_Mutation | novel | c.782N>C | p.Gln261Pro | p.Q261P | Q8N5Y8 | protein_coding | deleterious(0.01) | possibly_damaging(0.464) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PARP16 | SNV | Missense_Mutation | novel | c.353N>A | p.Pro118His | p.P118H | Q8N5Y8 | protein_coding | deleterious(0.01) | possibly_damaging(0.632) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PARP16 | SNV | Missense_Mutation | rs374649627 | c.463N>T | p.Arg155Cys | p.R155C | Q8N5Y8 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP16 | SNV | Missense_Mutation | novel | c.256N>A | p.Val86Met | p.V86M | Q8N5Y8 | protein_coding | tolerated(0.14) | benign(0.003) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP16 | SNV | Missense_Mutation | novel | c.706N>T | p.Asp236Tyr | p.D236Y | Q8N5Y8 | protein_coding | deleterious(0.01) | probably_damaging(0.951) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |